Why is Senores Pharma. falling/rising?

As of 14-Aug, Senores Pharmaceuticals Ltd is currently priced at 675.95, reflecting a decline of 4.85 points or 0.71%. The stock has recently underperformed its sector by 0.83% and has experienced a trend reversal, falling after three consecutive days of gains. Despite this drop, the stock has shown positive performance over the past week and month, with returns of 0.59% and 10.42%, respectively. The company has reported strong financial growth, with net sales increasing at an annual rate of 85.60% and operating profit at 130.72%. However, it also faces challenges, including a high valuation with a price-to-book ratio of 4 and a relatively low return on equity of 7.4%. Additionally, institutional investor participation has decreased slightly, which may indicate a lack of confidence among more sophisticated investors.
In the broader market context, while Senores Pharmaceuticals has outperformed the Sensex over the past week and month, the overall market has seen a slight decline, with the Sensex down by 0.03% over the past week and 2.01% over the past month. This suggests that while the stock has shown resilience in its recent performance, the broader market conditions may be contributing to its current price decline. The stock's liquidity remains adequate for trading, but the falling participation from institutional investors could be a concern for future price movements, as these investors typically have more resources to analyze the company's fundamentals.